International normalized ratio (INR) < .; partial thromboplastin time (PTT) < . upper limit of normal (ULN); d-dimer < ng/mL
International normalized ratio (INR) =< . and partial thromboplastin time (PPT) =<  seconds above the upper limit of normal (ULN)
International normalized ratio (INR)/partial thromboplastin time (PTT) has to be =< . x ULN
International normalized ratio (INR) and partial thromboplastin time (PTT) < . x ULN
International normalized ratio (INR) and activated partial thromboplastin time (PTT) < . x upper limit of normal (ULN) provided the patient is not on anticoagulation therapy
International normalized ratio (INR)/partial thromboplastin time (PTT) =< . x ULN; unless patient is on therapeutic anticoagulation
Serum coagulation studies (international normalized ratio [INR]/partial thromboplastin time [PTT]) and platelet counts suitable for surgery per surgeon discretion
For patients undergoing serial tumor biopsies, international normalized ratio (INR) and activated partial thromboplastin time (PTT) must be within . X the upper limit of normal
Normal blood coagulation as evidenced by partial thromboplastin time (PTT) < . IULN and international normalized ratio (INR) < .
Within  days prior to first dose of study drug treatment: International normalized ratio (INR) and partial thromboplastin time (PTT) =< . x ULN
Serum prothrombin time, international normalized ratio (INR) and partial thromboplastin times which fall within normal limits or levels outside the normal range determined not to be clinically significant by the PI
International normalized ratio (INR) and partial thromboplastin time (PTT) =< . x ULN
International normalized ratio ?.  ULN and partial thromboplastin time ? seconds above ULN.
Only for patients who test positive for hepatitis B virus or hepatitis C virus: partial thromboplastin time (PTT)/international normalized ratio (INR) =< ULN (institutional)
Subjects with coagulopathies, including thrombocytopenia with platelet count < ,, international normalized ratio (INR) > . and partial thromboplastin time >  sec
International normalized ratio (INR) > . and a partial thromboplastin time (PTT) >  seconds
Adequate coagulation system defined as an international normalized ratio (INR) of less than . and a partial thromboplastin time (PTT) of less than 
Partial thromboplastin time (PTT) =< , international normalized ratio (INR) =< . institutional ULN unless on warfarin therapy (investigator would need to determine if safe for participant to stop warfarin prior to [optional] biopsy)
International normalized ratio (INR)/partial thromboplastin time (PTT) within . x upper limit of normal (Common Terminology Criteria for Adverse Events [CTCAE] . grade  abnormality is acceptable)
Abnormal laboratory values as defined by protocol for creatinine, creatinine clearance, aspartate transaminase (AST) or alanine transaminase (ALT), total bilirubin, international normalized ration (INR), partial thromboplastin time (PTT) or activated partial thromboplastin time (aPPT), unless these abnormalities are due to underlying lymphoma
International normalized ratio (INR) =< . and partial thromboplastin time (PTT) within normal limits; (patients who are on therapeutic anticoagulation with warfarin should have documentation of INR =< . or PTT within normal limits prior to initiating that therapy)
Partial thromboplastin time (PTT) must be =<  X upper normal limit of institution's normal range and INR (international normalized ratio) < ; subjects on anticoagulant (such as Coumadin) must have a PTT =<  X upper normal limit of institution's normal range and INR (international normalized ratio) < 
International normalized ratio (INR)/ partial thromboplastin time (PTT) =< . x ULN
Patients must have an International Normalized Ratio (INR) < . and a partial thromboplastin time (PTT) no greater than upper limits of normal within  week prior to randomization
Activated partial thromboplastin time (APTT) must not exceed . seconds (normal range .-. seconds); international normalized ratio (INR) must not exceed . (normal range .-.)
International Normalized Ratio (INR) and activated partial thromboplastin time [PTT] ? .ULN, if not therapeutically anticoagulated.
International normalized ratio (INR) and partial thromboplastin time (PTT) </=. times ULN (upper limit of normal)
International normalized ratio (INR) < . and a partial thromboplastin time (PT)/partial thromboplastin time (PTT) within normal limits; patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate; for patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly (INR must be therapeutic in the range of -)
The participant either has adequate coagulation function as defined by international normalized ratio (INR) ? . and partial thromboplastin time (PTT) no more than  seconds above the ULN, or is on a stable dose of anticoagulant
International normalized ratio (INR)/ partial thromboplastin time (PTT) =< . x ULN
International Normalized Ratio (INR) ?. and a partial thromboplastin time (PTT) ? seconds above the ULN.
An international normalized ratio (INR) > ., or a partial thromboplastin time (PTT) >  seconds
Subjects unable to undergo routine endoscopy with biopsy:\r\n* Women who are pregnant or breastfeeding\r\n* Prothrombin time < % of control; partial thromboplastin time (PTT) >  sec, or international normalized ratio (INR) > .\r\n* Inability to tolerate sedated upper endoscopy due to cardio-pulmonary instability or other significant medical issues
Partial thromboplastin time (PTT) greater than  seconds (sec) or international normalized ratio (INR) greater than .
Subjects with coagulopathies, including thrombocytopenia with platelet count < ,, international normalized ratio (INR) > . and partial thromboplastin time >  sec
International Normalized Ratio (INR) and activated Partial Thromboplastin Time [PTT] within normal institutional limits
internal normalized ratio and partial thromboplastin time <.x upper limit of normal